What labs and diagnostics should be ordered for a newborn with suspected Congenital Adrenal Hyperplasia (CAH) due to lack of newborn screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

For suspected congenital adrenal hyperplasia (CAH) in a newborn without screening, I recommend ordering serum 17-hydroxyprogesterone (17-OHP) as the primary diagnostic test, along with electrolytes (sodium, potassium, chloride), blood glucose, plasma renin activity, and serum aldosterone. A comprehensive adrenal steroid panel including 11-deoxycortisol, androstenedione, testosterone, and DHEA-sulfate will help characterize the specific enzyme deficiency, as suggested by 1. Collect blood samples before starting any steroid treatment if the patient is stable. An ACTH stimulation test may be necessary to confirm the diagnosis in borderline cases, as seen in 2. Obtain a karyotype for all infants with ambiguous genitalia. Abdominal/pelvic ultrasound should be performed to evaluate adrenal glands and internal genital structures. Urinalysis for specific gravity and urinary steroid profiling can provide additional diagnostic information. These tests are crucial because CAH, most commonly caused by 21-hydroxylase deficiency, can present with salt-wasting crisis, ambiguous genitalia in females, or may be asymptomatic initially in males, as discussed in 3. Early diagnosis is essential to prevent life-threatening adrenal crisis, especially in salt-wasting forms, and to guide appropriate hormone replacement therapy. It is also important to consider that some cases of CAH may be missed on newborn screening, as noted in 2, and that non-CAH primary adrenal insufficiency may present with similar symptoms, as seen in 4. Furthermore, the use of 21-deoxycortisol as a more specific marker for 21OHD has been suggested, as discussed in 5.

Some key points to consider when ordering labs and diagnostics for suspected CAH in a newborn without screening include:

  • The importance of early diagnosis to prevent life-threatening adrenal crisis
  • The need for a comprehensive adrenal steroid panel to characterize the specific enzyme deficiency
  • The use of ACTH stimulation testing to confirm the diagnosis in borderline cases
  • The importance of obtaining a karyotype for all infants with ambiguous genitalia
  • The role of abdominal/pelvic ultrasound in evaluating adrenal glands and internal genital structures
  • The potential for non-CAH primary adrenal insufficiency to present with similar symptoms
  • The potential benefits of using 21-deoxycortisol as a more specific marker for 21OHD.

Overall, a thorough diagnostic workup is essential for suspected CAH in a newborn without screening, and should include a combination of laboratory tests, imaging studies, and clinical evaluation, as supported by 1, 3, 2, 4, 5.

Related Questions

Can Congenital Adrenal Hyperplasia (CAH) be missed on Newborn Screening?
What laboratory tests can differentiate between classical and non-classical Congenital Adrenal Hyperplasia (CAH)?
What does an elevated 17-hydroxyprogesterone (17-OPH) level indicate and how is it treated?
What are the normal age-related values of 17-Hydroxyprogesterone (17-OH) in children?
What enzyme deficiency is likely responsible for the conversion of 17-hydroxyprogesterone to 11-deoxycortisol in a newborn with congenital adrenal hyperplasia (CAH) and electrolyte imbalance?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, which has not grown but matured over 3 years, likely to be benign or malignant in a patient with a history of T1a kidney cancer?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.